Cardiografin en es it fr

Cardiografin Brand names, Cardiografin Analogs

Cardiografin Brand Names Mixture

  • No information avaliable

Cardiografin Chemical_Formula


Cardiografin RX_link

No information avaliable

Cardiografin fda sheet

Cardiografin msds (material safety sheet)

Cardiografin Synthesis Reference

No information avaliable

Cardiografin Molecular Weight

241.247 g/mol

Cardiografin Melting Point

250-255 oC (hydrochloride salt)

Cardiografin H2O Solubility

>20 mg/mL (dichloride salt)

Cardiografin State


Cardiografin LogP


Cardiografin Dosage Forms

No information avaliable

Cardiografin Indication

For the treatment of tetrahydrobiopterin (BH4) deficiency.

Cardiografin Pharmacology

Tetrahydrobiopterin (BH4) is used to convert several amino acids, including phenylalanine, to other essential molecules in the body including neurotransmitters. Tetrahydrobiopterin deficiency can be caused by mutations in GTP cyclohydrolase 1 (GCH1), 6-pyruvoyl-tetrahydropterin synthase/dimerization cofactor of hepatocyte nuclear factor 1 alpha (PCBD1), 6-pyruvoyltetrahydropterin synthase (PTS), and quinoid dihydropteridine reductase (QDPR) genes. These genes make the enzymes that are critical for producing and recycling tetrahydrobiopterin. If one of the enzymes fails to function correctly because of a gene mutation, little or no tetrahydrobiopterin is produced. As a result, phenylalanine from the diet builds up in the bloodstream and other tissues and can damage nerve cells in the brain. High levels of phenylalanine can result in signs and symptoms ranging from temporary low muscle tone to mental retardation, movement disorders, difficulty swallowing, seizures, behavioral problems, progressive problems with development, and an inability to control body temperature.

Cardiografin Absorption

No information avaliable

Cardiografin side effects and Toxicity

No information avaliable

Cardiografin Patient Information

No information avaliable

Cardiografin Organisms Affected

Humans and other mammals